3. OBJECTIVES
HCQ, SSZ, LLM and MTX are classical drugs, which are used for the treatment of a variety of diseases. All of these drugs are official in different Pharmacopoeias. Some reports on characterization of their PRIs and DRIs are also available in literature. However, none of the report is in compliance with the recommendations of ICH guidelines for characterization of impurities in drug substances. Hence, the present study is designed to:

1. conduct forced degradation on selected DMARDs used in RA
2. develop HPLC method(s) for separation of each drug and its degradation products
3. characterize the major degradation product(s) of each drug through spectral analyses (IR, NMR and/or Mass) or LC-MS studies.
4. establish degradation pathways and inherent stability of the drug.